CCEL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
7.8M
+0.6%
7.8M
+1.2%
7.7M
-2.0%
7.8M
+0.2%
7.8M
Cost of Revenue
1.6M
-3.8%
1.7M
+1.2%
1.7M
-4.5%
1.7M
-3.7%
1.8M
Gross Profit
6.2M
+1.8%
6.1M
+1.2%
6.0M
-1.3%
6.1M
+1.4%
6.0M
Operating Expenses
4.0M
-18.1%
4.9M
-6.8%
5.3M
-47.8%
10.1M
+144.4%
4.1M
R&D
53.6K
-46.3%
99.8K
+51.7%
65.8K
-22.4%
84.8K
+37.6%
61.6K
SG&A
3.8M
-18.2%
4.6M
-7.9%
5.0M
-8.0%
5.4M
+40.6%
3.9M
Operating Income
2.2M
+83.2%
1.2M
+56.5%
765.1K
+119.3%
-3966787
-308.7%
1.9M
EBITDA
2.4M
+68.9%
1.4M
+42.8%
1.0M
+58.9%
635.1K
-70.4%
2.1M
Net Income
1.3M
+129.1%
554.6K
+1077.3%
47.1K
+101.2%
-3817433
-609.4%
749.4K
EPS (Basic)
$0.16
+128.6%
$0.07
+600.0%
$0.01
+102.1%
$-0.47
-622.2%
$0.09
EPS (Diluted)
$0.16
+128.6%
$0.07
+600.0%
$0.01
+102.1%
$-0.48
-633.3%
$0.09
Shares (Diluted)
8.1M
+0.1%
8.1M
-0.0%
8.1M
+2.3%
7.9M
-2.5%
8.1M
Cryo-Cell International (CCEL) โ€” Financials